AbstractBackground & AimsSerum 25-hydroxyvitamin D (S-25(OH)D) and nonalcoholic fatty liver disease (NAFLD) are correlated in many observational studies, whereas the causality of this association is uncertain, especially in European populations. We conducted a bidirectional Mendelian randomization study to determine the association between S-25(OH)D and NAFLD. MethodsSeven and six independent genetic variants associated with S-25(OH)D and… Continue reading Inverse association between serum 25-hydroxyvitamin D and nonalcoholic fatty liver disease
Category: Hepatology
Relationship of circulating total bilirubin, UDP-glucuronosyltransferases 1A1 and the development of non-alcoholic fatty liver disease: a cross-sectional study
This study aimed to investigate the correlation of circulating total bilirubin (TB) and UGT1A1 with NAFLD in Chinese Han population. Methods172 adults were enrolled from the Qingdao Municipal Hospital from May 2019 to October 2020. All individuals were examined with MRI-PDFF and divided into no steatosis, mild steatosis, moderate steatosis, and severe steatosis groups according… Continue reading Relationship of circulating total bilirubin, UDP-glucuronosyltransferases 1A1 and the development of non-alcoholic fatty liver disease: a cross-sectional study
Effect of liver steatosis on liver stiffness measurement in chronic hepatitis B patients with normal serum alanine aminotransferase levels: A multicentre cohort study
Liver steatosis is becoming increasingly common in patients with chronic hepatitis B (CHB), and its effect on liver stiffness measurement (LSM), as assessed by transient elastography, remains controversial. Seven hundred and fifty-five patients with CHB and normal serum alanine aminotransferase levels, who underwent vibration-controlled transient elastography and liver biopsy, were included in the study. We… Continue reading Effect of liver steatosis on liver stiffness measurement in chronic hepatitis B patients with normal serum alanine aminotransferase levels: A multicentre cohort study
The efficacy and tolerability of pharmacologically active interventions for alcohol-induced hangover symptomatology: A systematic review of the evidence from randomised placebo-controlled trials
To compare quantitatively the efficacy and tolerability of pharmacologically active interventions in the treatment and prevention of alcohol-induced hangover. MethodsSystematic review of placebo-controlled randomised trials in healthy adults that evaluated any pharmacologically active intervention in the treatment or prevention of hangover. We searched Medline, Embase, PsycINFO and CENTRAL from database inception until 1st August 2021.… Continue reading The efficacy and tolerability of pharmacologically active interventions for alcohol-induced hangover symptomatology: A systematic review of the evidence from randomised placebo-controlled trials
Hypoglycemia associated with direct-acting anti-hepatitis C virus drugs: An epidemiologic surveillance study of the FDA adverse event reporting system (FAERS)
Hypoglycemia induced by direct-acting antiviral agents (DAAs) for chronic hepatitis C virus (HCV) infection is a rare but potentially life-threatening adverse reaction, which led to warnings by competent authorities. We therefore aimed to examine the hypoglycemic safety signal for DAAs. MethodsReports to the US Food and Drug Administration Adverse Event Reporting System (FAERS) from 1… Continue reading Hypoglycemia associated with direct-acting anti-hepatitis C virus drugs: An epidemiologic surveillance study of the FDA adverse event reporting system (FAERS)
Food Insecurity is Associated with Mortality Among U.S. Adults with Nonalcoholic Fatty Liver Disease and Advanced Fibrosis
Food insecurity is a growing public health challenge in the U.S. and has been linked to nonalcoholic fatty liver disease (NAFLD) and advanced fibrosis. However, little is known of how food insecurity impacts mortality risk and healthcare utilization (HCU) in chronic liver disease. MethodsUsing a population-based cohort study of U.S. adults (≥20 years) in the… Continue reading Food Insecurity is Associated with Mortality Among U.S. Adults with Nonalcoholic Fatty Liver Disease and Advanced Fibrosis
Liver expression of IL-22, IL-22R1 and IL-22BP in patients with chronic hepatitis C with different fibrosis stages
Highlights•Liver biopsies at stage F1 to F3 expressed more IL-22 than F0 or F4. •The number of cells expressing IL-22R1 decreased as fibrosis increased. •There was an increase in Il-22BP staining in more advanced stages of fibrosis. •IL-22 pathway may be involved in the pathophysiology of liver fibrosis. AbstractLiver fibrosis is the result of an… Continue reading Liver expression of IL-22, IL-22R1 and IL-22BP in patients with chronic hepatitis C with different fibrosis stages
MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis
Patients with NASH, NAS≥4, and F≥2 (Fibro-NASH) are at highest risk for disease progression.➢Patients with Fibro-NASH are targeted for proof-of-concept NASH trials.➢MRI-PDFF and MR elastography are the most common primary and secondary endpoints in NASH trials, respectively.➢To identify Fibro-NASH, the MRI-AST (MAST) score was created based on these MRI techniques.➢The MAST score was proven to… Continue reading MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis
EDP-305 in patients with #NASH: A phase II double-blind placebo-controlled dose-ranging study
•EDP-305 is an oral farnesoid X receptor (FXR) agonist being developed to treat nonalcoholic steatohepatitis (NASH).•In a randomized, placebo-controlled study, 12-week study, EDP-305 reduced ALT levels and MRI-PDFF•These results support further development of EDP-305 in patients with NASH with longer term studies. ABSTRACTBackground & AimsEDP-305 is an oral farnesoid X receptor (FXR) agonist under development… Continue reading EDP-305 in patients with #NASH: A phase II double-blind placebo-controlled dose-ranging study
2 Medical News 